Regorafenib (Stivarga) falls under the oral multi-kinase inhibitor, which was developed by Bayer which specifically targets the angiogenic, stromal and oncogenic RTK (Receptor Tyrosine Kinase).
Regorafenib 40 mg demonstrates anti-angiogenic activity because of its dual targeted VEGFR2 TIE2 tyrosine kinase inhibition.
Since the year 2009, it has been studied as a potential treatment option in multiple tumor types. By 2015 it got a couple of US approvals for the advanced cancers.
In the month of May, 2012, Bayer submitted a New Drug Application for Regorafenib in order to treat the Metastatic Colorectal Cancer.
In the month of June, 2012, the US Food and Drug Administration granted priority review to the New Drug Application for Bayer's Regorafenib in order to treat patients with Metastatic Colorectal Cancer.
In the month of August, 2012, Bayer submitted a New Drug Application for Regorafenib in order to treat Gastrointestinal Stromal Tumors (GIST).
In the month of September, 2012, the Food and Drug Administration approved regorafenib in order to treat Advanced Colorectal Cancer.
In the month of February, 2013, the Food and Drug Administration approved regorafenib in order to treat the Advanced Gastrointestinal Stromal Tumors.
In the month of April, 2017, the Food and Drug Administration expanded the approved use of regorafenib in order to treat Hepatocellular Carcinoma.
The regorafenib 40 mg price in india is around 59,294 INR for a supply of 28 tablets, depending on the pharmacy/wholesaler you visit. Any WHO-GDP & ISO certified pharmaceutical wholesaler company would be best to buy regorafenib.